What to know about Trump's coronavirus treatment regimen
Hello,
What a weekend.
Since being diagnosed with COVID-19 on Thursday, President Donald Trump has received a number of treatments. Those include an experimental antibody therapeutic from drugmaker Regeneron and the antiviral remdesivir.
On Sunday, White House physician Sean Conley said that Trump was feeling better, but noted that the president had received dexamethasone, a steroid usually reserved for patients with more serious cases, Aylin Woodward reported. Trump also received supplemental oxygen on Friday and Saturday.
Let's dive in.
Trump's doctors are targeting a 'sweet spot' in fighting COVID-19 by using experimental treatments early, but physicians caution the data is limited
- President Donald Trump is taking several drugs to combat COVID-19, a combination approach that critical care doctors called rational but untested.
- Over the past few days, the president confirmed his diagnosis, was injected with an experimental antibody cocktail, transported to Walter Reed Medical Center, and given an IV infusion of the antiviral drug remdesivir.
- Giving the antibody drug and remdesivir early on should help COVID-19 patients in fighting the disease, physicians told Business Insider.
- But the two drugs have not been tested in combination. "We are clearly in a data-free zone right here," said Dr. Taison Bell, an infectious-disease expert and critical-care physician who has studied remdesivir.
Read the full story from Andrew Dunn here>>
POWER PLAYERS: The 15 leaders at Microsoft shaping the tech giant's growing healthcare ambitions
- Microsoft is making healthcare a priority through important hires, products, and partnerships.
- The $1.57 trillion tech giant chose healthcare to roll out its first industry-specific cloud service.
- Here are the 15 leaders that experts and the company told us are critical to Microsoft's healthcare business.
Read the full story from Blake Dodge and Ashley Stewart here>>
Novartis salaries revealed: From $49,608 to $195,686, find out how much the Swiss pharma giant pays its employees in the US
- The Swiss pharmaceutical giant Novartis is a leader in the drug industry, commanding a market value of $200 billion and employing more than 100,000 people around the globe.
- Business Insider's analysis shows that Novartis hires employees in the US at salaries ranging from around $50,000 to mid-six-figures.
- Our analysis includes salaries for positions from scientists to global directors, The roles we analyzed include: science, data, solutions, engineering, leadership, and more.
Read the full story from Maddy Simpson, Andrew Dunn, and Alex Nicoll here>>
More stories we're reading:
- MyoKardia soars 59% after Bristol-Myers agrees to acquire it for $13 billion in cash (Markets Insider)
- Doctors need training to understand how AI can help them care for patients (Wired)
- The 26 best books to read if you want to disrupt US healthcare, according to top young leaders in the $3.6 trillion industry (Business Insider)
- Hospitals have learned their lesson when it comes to supplying PPE (Fierce Healthcare)
Subscribe to our newsletter here!
- Lydia